These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Studies on the mechanism of selective retention of porphyrins and metalloporphyrins by cancer cells. Megnin F; Faustino PJ; Lyon RC; Lelkes PI; Cohen JS Biochim Biophys Acta; 1987 Jul; 929(2):173-81. PubMed ID: 3593779 [TBL] [Abstract][Full Text] [Related]
3. Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice. Furmanski P; Longley C Cancer Res; 1988 Aug; 48(16):4604-10. PubMed ID: 3396012 [TBL] [Abstract][Full Text] [Related]
4. Metalloporphyrin contrast agents for magnetic resonance imaging of human tumors in mice. Patronas NJ; Cohen JS; Knop RH; Dwyer AJ; Colcher D; Lundy J; Mornex F; Hambright P; Sohn M; Myers CE Cancer Treat Rep; 1986 Mar; 70(3):391-5. PubMed ID: 3955550 [TBL] [Abstract][Full Text] [Related]
5. Metalloporphyrin magnetic resonance contrast agents. Feasibility of tumor-specific magnetic resonance imaging. van Zijl PC; Place DA; Cohen JS; Faustino PJ; Lyon RC; Patronas NJ Acta Radiol Suppl; 1990; 374():75-9. PubMed ID: 1966973 [TBL] [Abstract][Full Text] [Related]
6. Binding of manganese and iron tetraphenylporphine sulfonates to albumin is relevant to their contrast properties. Yushmanov VE; Tominaga TT; Borissevitch IE; Imasato H; Tabak M Magn Reson Imaging; 1996; 14(3):255-61. PubMed ID: 8725191 [TBL] [Abstract][Full Text] [Related]
7. MRI contrast-dose relationship of manganese(III)tetra(4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T. Place DA; Faustino PJ; Berghmans KK; van Zijl PC; Chesnick AS; Cohen JS Magn Reson Imaging; 1992; 10(6):919-28. PubMed ID: 1461089 [TBL] [Abstract][Full Text] [Related]
8. Manganese(III) porphyrin oligomers as high-relaxivity MRI contrast agents. Lu HS; Wang MY; Ying FP; Lv YY Bioorg Med Chem; 2021 Apr; 35():116090. PubMed ID: 33639594 [TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Ni Y; Petré C; Miao Y; Yu J; Cresens E; Adriaens P; Bosmans H; Semmler W; Baert AL; Marchal G Invest Radiol; 1997 Dec; 32(12):770-9. PubMed ID: 9406018 [TBL] [Abstract][Full Text] [Related]
10. Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging. A study of human carcinoma, lymphoma, and fibrosarcoma in mice. Ogan MD; Revel D; Brasch RC Invest Radiol; 1987 Oct; 22(10):822-8. PubMed ID: 3429177 [TBL] [Abstract][Full Text] [Related]
11. The positive influence of fullerene derivatives bonded to manganese(III) porphyrins on water proton relaxation. Zou T; Zhen M; Chen D; Li R; Guan M; Shu C; Han H; Wang C Dalton Trans; 2015 May; 44(19):9114-9. PubMed ID: 25899301 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of manganese meso-sulfonatophenyl porphyrins: contrast-enhancing agents for tumors. Fiel RJ; Musser DA; Mark EH; Mazurchuk R; Alletto JJ Magn Reson Imaging; 1990; 8(3):255-9. PubMed ID: 2366638 [TBL] [Abstract][Full Text] [Related]
13. Test of Electron Delocalization Effects on Water-Proton Spin-Lattice Relaxation by Bromination of [Tetrakis(4-sulfonatopheny)porphine]manganese. Bryant LH; Hodges MW; Bryant RG Inorg Chem; 1999 Mar; 38(5):1002-1005. PubMed ID: 11670874 [TBL] [Abstract][Full Text] [Related]
14. Complementary strategies for developing Gd-free high-field T₁ MRI contrast agents based on Mn(III) porphyrins. Cheng W; Haedicke IE; Nofiele J; Martinez F; Beera K; Scholl TJ; Cheng HL; Zhang XA J Med Chem; 2014 Jan; 57(2):516-20. PubMed ID: 24328058 [TBL] [Abstract][Full Text] [Related]
15. Mn-porphyrins as novel molecular magnetic resonance imaging contrast agents. Mouraviev V; Venkatraman TN; Tovmasyan A; Kimura M; Tsivian M; Mouravieva V; Polascik TJ; Wang H; Amrhein TJ; Batinic-Haberle I; Lascola C J Endourol; 2011 Nov; ():1420-4. PubMed ID: 22050509 [TBL] [Abstract][Full Text] [Related]
16. Mn porphyrins as novel molecular magnetic resonance imaging contrast agents. Mouraviev V; Venkatraman TN; Tovmasyan A; Kimura M; Tsivian M; Mouravieva V; Polascik TJ; Wang H; Amrhein TJ; Batinic-Haberle I; Lascola C J Endourol; 2012 Nov; 26(11):1420-4. PubMed ID: 22783812 [TBL] [Abstract][Full Text] [Related]
17. Quantitative magnetic resonance imaging of rat brain tumors: in vivo NMR relaxometry for the discrimination of normal and pathological tissues. Hoehn-Berlage M; Bockhorst K Technol Health Care; 1994 Dec; 2(4):247-54. PubMed ID: 7842309 [TBL] [Abstract][Full Text] [Related]
18. Binding of a dimeric manganese porphyrin to serum albumin: towards a gadolinium-free blood-pool T1 MRI contrast agent. Cheng W; Ganesh T; Martinez F; Lam J; Yoon H; Macgregor RB; Scholl TJ; Cheng HL; Zhang XA J Biol Inorg Chem; 2014 Feb; 19(2):229-35. PubMed ID: 24407461 [TBL] [Abstract][Full Text] [Related]
19. Water-soluble porphyrins as a dual-function molecular imaging platform for MRI and fluorescence zinc sensing. Zhang XA; Lovejoy KS; Jasanoff A; Lippard SJ Proc Natl Acad Sci U S A; 2007 Jun; 104(26):10780-5. PubMed ID: 17578918 [TBL] [Abstract][Full Text] [Related]
20. Proton relaxation enhancement by manganese(III)TPPS4 in a model tumor system. Fiel RJ; Button TM; Gilani S; Mark EH; Musser DA; Henkelman RM; Bronskill MJ; van Heteren JG Magn Reson Imaging; 1987; 5(2):149-56. PubMed ID: 3586881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]